Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

Servier strengthens its R&D pipeline by acquiring Symphogen’s antibody pipeline and next-generation antibody technologies. -- Symphogen becomes the antibody center of excellence within Servier. -- Securing Servier’s ambition to become a recognized player in oncology.